Variables affecting outcomes after allogeneic hematopoietic stem cell transplant for cerebral adrenoleukodystrophy
Robert Chiesa, Jaap Jan Boelens, Christine N Duncan, Jörn-Sven Kühl, Caroline Sevin, Neena Kapoor, Vinod K Prasad, Caroline A Lindemans, Simon A Jones, Hernan M Amartino, Mattia Algeri, Nancy Bunin, Cristina Diaz-de-Heredia, Daniel J Loes, Esther Shamir, Alison Timm, Elizabeth McNeil, Andrew C Dietz, Paul J Orchard, Robert Chiesa, Jaap Jan Boelens, Christine N Duncan, Jörn-Sven Kühl, Caroline Sevin, Neena Kapoor, Vinod K Prasad, Caroline A Lindemans, Simon A Jones, Hernan M Amartino, Mattia Algeri, Nancy Bunin, Cristina Diaz-de-Heredia, Daniel J Loes, Esther Shamir, Alison Timm, Elizabeth McNeil, Andrew C Dietz, Paul J Orchard
Abstract
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) in early cerebral adrenoleukodystrophy can stabilize neurologic function and improve survival but has associated risks including transplant-related mortality (TRM), graft failure, and graft-versus-host disease (GVHD). An observational study of 59 patients with median age at allo-HSCT of 8 years addressed impact of donor source, donor match, conditioning regimen, and cerebral disease stage on first allo-HSCT outcomes. Efficacy analyses included 53 patients stratified by disease category: advanced disease (AD; n = 16) with Loes score >9 or neurological function score (NFS) >1 and 2 early disease (ED) cohorts (ED1 [Loes ≤4 and NFS ≤1; n = 24] and ED2 [Loes >4-9 and NFS ≤1; n = 13]). Survival free of major functional disabilities and without second allo-HSCT at 4 years was significantly higher in the ED (66%) vs AD (41%) cohort (P = .015) and comparable between ED1 and ED2 cohorts (P = .991). The stabilization of neurologic function posttransplant was greater in the ED vs AD cohort, with a median change from baseline at 24 months after allo-HSCT in NFS and Loes score, respectively, of 0 and 0.5 in ED1 (n = 13), 0.5 and 0 in ED2 (n = 6), and 2.5 and 3.0 (n = 4) in AD cohort. TRM was lower in the ED (7%) compared with the AD (22%) cohort; however, the difference was not significant (P = .094). Transplant-related safety outcomes were also affected by transplant-related characteristics: graft failure incidence was significantly higher with unrelated umbilical cord grafts vs matched related donors (P = .039), and acute GVHD and graft failure incidences varied by conditioning regimen. This study was registered at www://clinicaltrials.gov as #NCT02204904.
© 2022 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.
Figures
References
- Bezman L, Moser AB, Raymond GV, et al. . Adrenoleukodystrophy: incidence, new mutation rate, and results of extended family screening. Ann Neurol. 2001;49(4):512-517.
- Wiesinger C, Eichler FS, Berger J. The genetic landscape of X-linked adrenoleukodystrophy: inheritance, mutations, modifier genes, and diagnosis. Appl Clin Genet. 2015;8:109-121.
- Moser HW, Mahmood A, Raymond GV. X-linked adrenoleukodystrophy. Nat Clin Pract Neurol. 2007;3(3):140-151.
- Raymond GV, Moser AB, Fatemi A. X-linked adrenoleukodystrophy. In: Adam MP, Ardinger HH, Pagon RA, et al., eds. GeneReviews((R)). Seattle, WA: University of Washington, Seattle; 1999:1-17.
- Mahmood A, Raymond GV, Dubey P, Peters C, Moser HW. Survival analysis of haematopoietic cell transplantation for childhood cerebral X-linked adrenoleukodystrophy: a comparison study. Lancet Neurol. 2007;6(8):687-692.
- Eichler F, Duncan C, Musolino PL, et al. . Hematopoietic stem-cell gene therapy for cerebral adrenoleukodystrophy. N Engl J Med. 2017;377(17):1630-1638.
- Raymond GV, Aubourg P, Paker A, et al. . Survival and functional outcomes in boys with cerebral adrenoleukodystrophy with and without hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2019;25(3):538-548.
- Aubourg P, Blanche S, Jambaqué I, et al. . Reversal of early neurologic and neuroradiologic manifestations of X-linked adrenoleukodystrophy by bone marrow transplantation. N Engl J Med. 1990;322(26):1860-1866.
- Miller WP, Rothman SM, Nascene D, et al. . Outcomes after allogeneic hematopoietic cell transplantation for childhood cerebral adrenoleukodystrophy: the largest single-institution cohort report. Blood. 2011;118(7):1971-1978.
- Loes DJ, Hite S, Moser H, et al. . Adrenoleukodystrophy: a scoring method for brain MR observations. AJNR Am J Neuroradiol. 1994;15(9): 1761-1766.
- Loes DJ, Fatemi A, Melhem ER, et al. . Analysis of MRI patterns aids prediction of progression in X-linked adrenoleukodystrophy. Neurology. 2003;61(3):369-374.
- Moser HW, Loes DJ, Melhem ER, et al. . X-Linked adrenoleukodystrophy: overview and prognosis as a function of age and brain magnetic resonance imaging abnormality. A study involving 372 patients. Neuropediatrics. 2000;31(5):227-239.
- Beam D, Poe MD, Provenzale JM, et al. . Outcomes of unrelated umbilical cord blood transplantation for X-linked adrenoleukodystrophy. Biol Blood Marrow Transplant. 2007;13(6):665-674.
- Fernandes JF, Bonfim C, Kerbauy FR, et al. . Haploidentical bone marrow transplantation with post transplant cyclophosphamide for patients with X-linked adrenoleukodystrophy: a suitable choice in an urgent situation. Bone Marrow Transplant. 2018;53(4):392-399.
- Bartelink IH, van Reij EM, Gerhardt CE, et al. . Fludarabine and exposure-targeted busulfan compares favorably with busulfan/cyclophosphamide-based regimens in pediatric hematopoietic cell transplantation: maintaining efficacy with less toxicity. Biol Blood Marrow Transplant. 2014;20(3):345-353.
- Gupta A, Downey M, Shanley R, et al. . Reduced-toxicity (BuFlu) conditioning is better tolerated but has a higher second transplantation rate compared to myeloablative conditioning (BuCy) in children with inherited metabolic disorders. Biol Blood Marrow Transplant. 2020;26(3):486-492.
- Peters C, Charnas LR, Tan Y, et al. . Cerebral X-linked adrenoleukodystrophy: the international hematopoietic cell transplantation experience from 1982 to 1999. Blood. 2004;104(3):881-888.
- Barker JN, Kurtzberg J, Ballen K, et al. . Optimal practices in unrelated donor cord blood transplantation for hematologic malignancies. Biol Blood Marrow Transplant. 2017;23(6):882-896.
- Glucksberg H, Storb R, Fefer A, et al. . Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors. Transplantation. 1974;18(4):295-304.
- Lee SJ. Classification systems for chronic graft-versus-host disease. Blood. 2017;129(1):30-37.
- Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53(282):457-481.
- Kalbfleisch JD, Prentice RL. The Statistical Analysis of Failure Time Data. New York, NY: Wiley; 1980.
- Kühl JS, Kupper J, Baqué H, et al. . Potential risks to stable long-term outcome of allogeneic hematopoietic stem cell transplantation for children with cerebral X-linked adrenoleukodystrophy. JAMA Netw Open. 2018;1(3):e180769.
- Pierpont EI, Eisengart JB, Shanley R, et al. . Neurocognitive trajectory of boys who received a hematopoietic stem cell transplant at an early stage of childhood cerebral adrenoleukodystrophy. JAMA Neurol. 2017;74(6):710-717.
- Engelen M, Kemp S, de Visser M, et al. . X-linked adrenoleukodystrophy (X-ALD): clinical presentation and guidelines for diagnosis, follow-up and management. Orphanet J Rare Dis. 2012;7(1):51.
- Mallack EJ, Turk BR, Yan H, et al. . MRI surveillance of boys with X-linked adrenoleukodystrophy identified by newborn screening: meta-analysis and consensus guidelines. J Inherit Metab Dis. 2021;44(3):728-739.
- Lee S, Clinard K, Young SP, et al. . Evaluation of X-linked adrenoleukodystrophy newborn screening in North Carolina. JAMA Netw Open. 2020; 3(1):e1920356.
- Wiens K, Berry SA, Choi H, et al. . A report on state-wide implementation of newborn screening for X-linked adrenoleukodystrophy. Am J Med Genet A. 2019;179(7):1205-1213.
- Lampret BR, Remec ZI, Torkar AD, et al. . Expanded newborn screening program in Slovenia using tandem mass spectrometry and confirmatory next generation sequencing genetic testing. Zdr Varst. 2020;59(4):256-263.
- Barendsen RW, Dijkstra IME, Visser WF, et al. . Adrenoleukodystrophy Newborn Screening in the Netherlands (SCAN Study): the X-factor [published correction appears in Front Cell Dev Biol. 2021;9:631655]. Front Cell Dev Biol. 2020;8:499.
- Chiesa R, Wang J, Blok HJ, et al. . Hematopoietic cell transplantation in chronic granulomatous disease: a study of 712 children and adults. Blood. 2020;136(10):1201-1211.
- Lum SH, Miller WP, Jones S, et al. . Changes in the incidence, patterns and outcomes of graft failure following hematopoietic stem cell transplantation for Hurler syndrome. Bone Marrow Transplant. 2017;52(6):846-853.
- Pierpont EI, Nascene DR, Shanley R, et al. . Neurocognitive benchmarks following transplant for emerging cerebral adrenoleukodystrophy. Neurology. 2020;95(5):e591-e600.
Source: PubMed